Sterile pharmaceutical products get revised GMP by SFDA
China Food and Drug Administration (SFDA) has announced the implementation of the Good Manufacturing Practice for Drugs, 2010 revision, for sterile pharmaceutical products. As given in the implementation plan of Good Manufacturing Practice for Drugs (2010 Revision), which is referred to as the newly revised GMP, the production of blood products, vaccines, injections and other sterile pharmaceutical products are required to meet the requirements of the newly revised GMP before December 31, 2013.
China Food and Drug Administration (SFDA) is responsible for drafting laws and regulations, regarding administration and supervision of food safety, drugs, medical devices and cosmetics. It is also in charge of formulating the regulations of food administrative licensing and publication of natural pharmacopeia. Such guidelines and regulations related to food and drug safety plans and their implementation are under their control.